Beam Therapeutics Inc. (BEAM)

21.38 -0.22 (-1.02%) 收市：04:00PM EDT

Beam Therapeutics Inc.

238 Main Street
9th Floor
Cambridge, MA 02142-1016
United States
857 327 8775
https://beamtx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 436

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. John M. Evans M.B.A.	CEO & Director	1.11M	9.03M	1978
Dr. Giuseppe Ciaramella Ph.D.	President	933.2k	1.27M	1969
Ms. Terry-Ann Burrell M.B.A.	CFO & Treasurer	711.15k	無	1977
Dr. Feng Zhang Ph.D.	Co-Founder	無	無	無
Dr. David R. Liu Ph.D.	Co-Founder	無	無	無
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder	無	無	無
Dr. Nicole Gaudelli Ph.D.	Co-Founder	無	無	無
Dr. Alexis Komor Ph.D.	Co-Founder	無	無	無
Dr. Manmohan Singh Ph.D.	Chief Technology Officer	無	無	無
Dr. Gopi Shanker Ph.D.	Chief Scientific Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

公司管治

截至 2024年4月1日 止，Beam Therapeutics Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：9；股東權利：5；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。